PRC
BPMC

Pearl River Capital’s Blueprint Medicines BPMC Stock Holding History

Pearl River Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,476
Closed -$218K – 411
2021
Q2 		$218K Buy
+2,476
New +$227K 0.06% 383
2020
Q2 		– Sell
-100
Closed -$6K – 313
2020
Q1 		$6K Buy
+100
New +$6.43K 0.01% 414
2019
Q1 		– Sell
-100
Closed -$5K – 399
2018
Q4 		$5K Buy
+100
New +$6.08K 0.02% 707

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Pearl River Capital's BPMC Position: Q3 2021 in Review

Pearl River Capital sold out of Blueprint Medicines (BPMC) in Q3 2021, closing a stake of 2,476 shares — an estimated $218K sold.

Pearl River Capital first reported a position in BPMC in Q4 2018 and held it in 3 quarters. The position peaked at $218K in Q2 2021. 288 funds tracked by Wall St. Rank hold BPMC as of Q3 2021.

  • Pearl River Capital reported no remaining Blueprint Medicines position as of Q3 2021 after selling out during the quarter.
  • Pearl River Capital sold 2,476 Blueprint Medicines shares in Q3 2021, an estimated $218K.
  • Pearl River Capital first reported a position in Blueprint Medicines in Q4 2018 and held it in 3 quarters.
  • Pearl River Capital's Blueprint Medicines position peaked at $218K in Q2 2021.
  • 288 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2021.

Based on Pearl River Capital's 13F filing for Q3 2021, filed 12 Nov 2021.